



ORIGINAL RESEARCH PAPER

Medicine

A STUDY OF CLINICAL PROFILE OF PATIENTS WITH COMMUNITY VERSUS HOSPITAL ACQUIRED ACUTE KIDNEY DISEASE

KEY WORDS: Acute kidney injury (AKI), Community acquired (CA-AKI), Hospital acquired (HA-AKI)

Samrudhi Bagaria*

Department of General Medicine, Geetanjali Medical College & Hospital, Udaipur, Rajasthan *Corresponding Author

Animesh Gaur

Department of General Medicine, Pacific Medical College & Hospital, Udaipur, Rajasthan

ABSTRACT

Background: Acute kidney injury (AKI) depicts the abrupt decline in renal function mostly occurring over the course hours to days. For Acute Dialysis Quality Initiative (ADQI) Modified RIFLE criteria & AKIN criteria were proposed earlier, are now replaced by KDIGO clinical practice guidelines. We aim to evaluate the characteristics and prognosis of hospital acquired AKI (HA-AKI) & community acquired AKI (CA-AKI) patients who were admitted in the hospital for their clinical profile and outcome.

Methods: This is a prospective cross sectional hospital based study design on comparison of HA-AKI & CA-AKI patients AKI irrespective of their co-morbidities & falling under Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Impaired renal function at the time of admission to the hospital was considered as CA-AKI. AKI developing after 48 h of hospitalization was considered as HA-AKI.

RESULTS: Frequency of CA-AKI was significantly higher as compared to HA-AKI. ($p < 0.001$). The Difference in serum creatinine values at admission, after 48 hrs and at 7th day from admission in both, CA-AKI as well as HA-AKI patients was found to be statistically significant ($p < 0.001$). Highest percentage of patients were in KDIGO stage 3, in both the groups of AKI (50.9% and 61.1% in CA-AKI and HA-AKI respectively). Need for dialysis was higher in patients with HA-AKI (44.4%) as compared to CA-AKI (26.3%). Patients with CA-AKI had significantly higher rate of complete recovery than HA-AKI patients. Higher mortality rates were seen in patients with HA-AKI (38.8%) as compared to CA-AKI (4.9%). Thus, there was significant association between outcome of patients and type of AKI ($p < 0.001$).

Conclusion: The frequency of community acquired AKI was much higher as compared to hospital acquired AKI. HA-AKI is common in ICUs, whereas CA-AKI is common in medical wards. Higher mortality was found in HA-AKI than CA-AKI. Patients with CA-AKI have better short and long-term outcomes as compared to HA-AKI. The reason may be the difference in aetiology as most patients of CA-AKI had volume depletion which could be corrected easily.

INTRODUCTION

Acute kidney injury depicts the abrupt decline in renal function mostly occurring over the course (hours to days) and ends in retention of metabolic waste products and dysregulation of fluid, electrolytes & acid-base homeostasis.^{1,2} The etiological spectrum of AKI is notably different between developing and developed nations. It is related to environmental, social and economic circumstances. Sepsis, surgery and trauma are the most common causes of AKI in developed countries. In developing countries, acute diarrheal diseases and tropical diseases still prevail.³ The aetiology, course, and outcome of AKI differ in various parts of India.^{4,5} In 2004, the Acute Dialysis Quality Initiative (ADQI) group, comprising of experts in the fields of nephrology and critical care medicine, published the RIFLE classification^{6,8}. This was a new consensus and evidence-based definition for AKI.⁶ In 2007, a modified version of the RIFLE criteria was published by the AKI Network (AKIN), an international collaboration of nephrologists and intensivists, known as the AKIN criteria.⁹ This existing classification scheme for AKI has been replaced by KDIGO clinical practice guidelines (2012) which incorporates the better elements of both RIFLE and AKIN criteria.²

The kidneys are relatively unique among other organs of the body due to its ability to recover from almost complete loss of function. AKI may develop in a wide variety of settings including ambulatory, outpatients, hospitalized & particularly critically ill patients. AKI is associated with substantial morbidity and mortality.²

Although recovery of renal function occurs in majority of patients surviving an episode of AKI, many patients remain dialysis dependant or are left with severe renal impairment. More recently it has been recognized that even patients who have complete or near complete recovery of renal function are at increased risk of CKD and that superimposition of AKI on CKD is associated with acceleration in the rate of progression to ESRD.

AKI maybe community acquired (CA-AKI) or hospital acquired (HA-AKI). CA-AKI is classified as patients diagnosed with impaired renal function at admission to the hospital. HA-AKI is classified as any patient developing AKI after 48 hours of admission to the hospital. Common causes of community acquired AKI include

volume depletion, adverse effects of medications and obstruction of the urinary tract. The most common clinical settings for hospital acquired AKI are sepsis, major surgical procedures, critical illness involving heart or liver failure, intravenous iodinated contrast administration and nephrotoxic drug administration². AKI complicates approximately 5-7% of hospital admission & 30% of admission to ICU patients. The risk of AKI is contributed by the acute insult and background morbidity. Acute insult may be in the forms of sepsis and hypoperfusion, toxicity, obstruction & parenchymal kidney disease. Background morbidities in the form of elderly, CKD, cardiac failure, liver failure, diabetes mellitus, vascular disease, nephrotoxic medication also contribute to insult.¹⁰ Since the implementation of Kidney Disease: Improving Global Outcomes (KDIGO) guidelines to diagnose and upgrade AKI, very few studies have evaluated the impact of its early recognition and management on subsequent outcome. There is lack of data to assess the impact of early AKI management on mortality, length of hospital stay, need of renal replacement therapy (RRT) or subsequent kidney function. In this study, we therefore aim to evaluate the characteristics and prognosis of hospital acquired AKI (HA-AKI) and community acquired AKI (CA-AKI) patients who were admitted in the hospital for their clinical profile and outcome.

AIMS AND OBJECTIVES

- 1) To study the clinical profile of patients with community and hospital acquired acute kidney injury.
- 2) To determine the frequency of community and hospital acquired acute kidney injury.

METHODS AND MATERIAL

Source of Data

The study was conducted in patients coming with elevated serum creatinine as per KDIGO guidelines and symptoms suggestive of acute kidney injury in the medical wards of Geetanjali Hospital, Udaipur

Sample Size: 120 cases

Sample procedure: Cross-sectional study

Duration: January 2017 – October 2018

INCLUSION CRITERIA

- All patients between 18 yrs to 75 yrs of age developing AKI irrespective of their co-morbidities.
- Diagnosing criteria for AKI – According to Kidney Disease: Improving Global Outcomes (KDIGO) criteria

EXCLUSION CRITERIA

- Age less than 18 years.
- Age more than 75 years.
- Diagnosed as Chronic kidney disease (CKD).
- CKD on maintenance hemodialysis (MHD).
- Pregnant females.

Study Design:

All the patients of age more than 18 years, admitted during the study period with acute kidney injury (AKI) or who developed acute kidney injury during the hospital stay have been included. Diagnosing criteria for AKI was according to KDIGO criteria. Patients below 18 years and above 75 years of age have been excluded, as KDIGO criteria has limitations for inclusion of these patients.

Impaired renal function at the time of admission to the hospital was considered as CA-AKI. AKI developing after 48 h of hospitalization was considered as HA-AKI.

- **CA-AKI = Community Acquired - Acute Kidney Injury**
- **HA-AKI = Hospital Acquired - Acute Kidney Injury**

OBSERVATION AND RESULTS

A total number of 120 cases of acute kidney injury (by KDIGO criteria), admitted in Geetanjali Medical College and Hospital, Udaipur, who met the inclusion criteria were studied. The following observations were noted:

TABLE 2: PREVALENCE OF AKI AND ITS DISTRIBUTION

Type of AKI	No of Patients	Z TEST	P VALUE
CA-AKI	102 (85%)	5.99	<0.001
HA-AKI	18 (15%)		
Total	120 (100%)		

Out of the 120 patients of AKI, 102 (85%) patients were classified as having CA-AKI and 18 (15%) patients as having HA-AKI. Thus, the frequency of CA-AKI was statistically significantly higher as compared to HA-AKI (P<0.001).

TABLE 3: AGE WISE DISTRIBUTION

Age (years)	CA-AKI	HA-AKI	No of patients
18-30	11 (10.7%)	0	11 (9.16%)
31-40	15 (14.7%)	1 (5.5%)	16 (13.33%)
41-50	20(19.6%)	6 (33.3%)	26 (21.66%)
51-60	26 (25.4%)	9 (50%)	35 (29.16%)
61-70	23 (22.5%)	2 (11.1%)	25 (20.83%)
>70	7 (6.8%)	0	7 (5.83%)
Total	102 (85%)	18 (15%)	120 (100%)
Mean Age	51.54 ± 14.93	53.22 ± 7.22	51.94 ± 14.11
T value	0.467		
P value	0.642		

Out of the 102 patients with CA-AKI, maximum i.e. 26 patients (25.4%) were from the age group of 51-60 years, followed by, 23 patients (22.5%) between 61-70 years, 20 patients (19.6%) between 41-50 years, 15 patients (14.7%) between 31-40 years and 11 patients (10.7%) between 18-30 years. Out of the 18 patients with HA-AKI, maximum i.e, 9 patients (50%) were from the age group of 51-60 years, followed by, 6 patients (33.3%) between 41-50 years, 2 patients (11.1%) between 61-70 years and 1 patient (5.5%) between 31-40 years. The mean age of patients with CA-AKI was 51.54 ± 14.93 and HA-AKI was 53.22 ± 7.22, which was statistically insignificant. Thus, the maximum number of patients with CA-AKI were in the 6th and 7th decades of life and in the 5th and 6th decades with HA-AKI.

TABLE 4: SEX WISE DISTRIBUTION

Sex	CA-AKI	HA-AKI	No of patients
Male	59 (57.8%)	11 (61.1%)	70 (58.3%)
Female	43 (42.1%)	7 (38.8%)	50 (41.6%)
Total	102 (85%)	18 (15%)	120 (100%)
x² value	0.067		
P value	>0.05		

Out of 120 patients of AKI, 70 patients (58.3%) were males, while 50 (41.6%) were females. The sex ratio was 1.4:1. Out of 102 patients with CA-AKI, 59 (57.8%) were males whereas, 43 (42.1%) were females. Out of 18 patients with HA-AKI, 11 (61.1%) were males while, 7 (38.8%) were females. Thus, CA-AKI and HA-AKI both have male predominance, but statistically there was insignificant association of gender and type of AKI (P>0.05).

TABLE 5: DISTRIBUTION OF CLINICAL PARAMETERS OF AKI

Clinical Parameters	CA-AKI	HA-AKI	No of patients
Diarrhea	57 (55.8%)	0	57 (47.5%)
Vomiting	61 (59.8%)	8 (44.4%)	69 (57.5%)
Oliguric Output	58 (56.8%)	15 (83.3%)	73 (60.8%)
Breathlessness	12 (11.7%)	8 (44.4%)	20 (16.6%)
Altered Sensorium	5 (4.9%)	7 (38.8%)	12 (10%)
Edema	8 (7.8%)	2 (11.1%)	10 (8.3%)
Non-specific Uremic Symptoms	23 (22.5%)	4 (22.2%)	27 (22.5%)
Jaundice	5 (4.9%)	6 (33.3%)	11 (9.2%)
x² value	44.85		
P value	<0.001		

The common clinical features observed in our study were oliguria (60.8%), vomiting (57.5%), diarrhea (47.5%), non-specific uremic symptoms (22.5%) breathlessness (16.6%), altered sensorium (10%), jaundice (9.2%) and edema (8.3%). Among patients of HA-AKI we have found high parameters of oliguria (83.3%), followed by vomiting (44.4%) and breathlessness (44.4%), while, in CA-AKI we have found high parameters of vomiting (59.8%), followed by oliguria (56.8%) and diarrhea (55.8%).

It has been observed that there was significant association between clinical features and type of AKI i.e. there was change in clinical feature with type of AKI (p<0.001).

TABLE 6: DISTRIBUTION OF PATIENTS ACCORDING TO CO-MORBIDITIES

Co-morbidities	CA-AKI	Ha-aki	Total	x ² value	P Value
PRESENT	15 (14.71%)	6 (33.33%)	21 (17.5%)	2.5	0.11
ABSENT	87 (85.29%)	12 (66.67%)	99 (82.5%)		
Total	102 (100%)	18 (100%)	120 (100%)		

Out of 102 CA-AKI patients, 15 (14.71%) had co- morbidities whereas, out of 18 patients of HA-AKI, 6 (33.33%) had co-morbidities. Thus, it has been observed that there was insignificant association between the presence of co- morbidities and type of AKI (p=0.11).

The percentage of co-morbidities in HA-AKI patients (6 out of 18 patients i.e. 33.33%) as compared to CA-AKI (15 out of 102 patients i.e. 14.71%) was more and this difference in proportion was statistically significant (P<0.001).

TABLE 7: TYPE OF CO MORBIDITY AND ITS DISTRIBUTION

Co-morbidities	CA-AKI	HA-AKI	No of patients
DM	5 (4.9%)	5 (27.7%)	10 (8.3%)
Hypertension	6 (5.8%)	0	6 (5%)
CAD	2 (1.9%)	1 (8.3%)	3 (2.5%)
CVA	1 (0.9%)	0	1 (0.8%)
COPD	1 (0.9%)	0	1 (0.8%)
Total	15 (14.71%)	6 (33.33%)	21 (17.5%)
2 value	5.48		
P value	0.241		

Co-morbidities were present in 21 (17.5%) patients of AKI. Out of these 21 AKI patients, 15 (71.43%) patients had CA-AKI and 6 (28.57%) patients had HA-AKI. Among the co-morbidities, diabetes was present in 10 (8.3%) patients, hypertension was present in 6 (5%) patients and CAD was present in 3 (2.5%) patients. CVA and COPD was present in 1(0.8%) patient each. The commonest co-morbidity in patients with CA-AKI was HTN (5.8%), while in HA-AKI was DM (27.7%). It has been observed that there was insignificant association between co- morbidities and type of AKI (p = 0.241).

TABLE 8: ETIOLOGICAL PROFILE OF AKI

Etiological	CA-AKI	HA-AKI	No of patients
Acute Diarrheal Disease	59 (57.8%)	0	59 (46.6%)
Snake Bite	25 (24.5%)	0	25 (20.8%)
Sepsis	0	12 (66.6%)	12 (10%)
Tropical Acute Febrile Illness	12 (11.7%)	0	12 (10%)
Acute Glomerulonephritis	1 (0.9%)	3 (16.6%)	4 (3.3%)
Ureteric calculi	3 (2.9%)	0	3 (2.5%)
Super vasmol Poisoning	2 (1.9%)	0	2 (1.6%)
Pigment Nephropathy	0	2 (11.1%)	2 (1.6%)
NSAID Induced	0	1 (5.5%)	1 (0.9%)
Total	102 (100%)	18 (100%)	120 (100%)
x² value	114.12		
P value	<0.001		

The most common cause of AKI was acute diarrheal disease (46.6%), followed by snake bite (20.8%), sepsis (10%), acute febrile illness due to tropical diseases (10%), acute glomerulonephritis (3.3%) and ureteric calculi (2.5%). In addition, higher frequency of sepsis (66.6%) was found in patients with HA-AKI, followed by, acute glomerulonephritis (16.6%), pigment nephropathy (11.1%) and NSAID induced (5.5%). Whereas, in patients of CA-AKI, higher frequency of acute diarrheal disease (57.8%) was found, followed by, snake bite (24.5%), acute febrile illness due to tropical diseases (11.7%) and ureteric calculi (3.9%) respectively. It has been observed that there was significant association between etiological profile and type of AKI (p < 0.001).

TABLE 9: HAEMATOLOGICAL AND BIOCHEMICAL PARAMETERS IN AKI

Biochemical parameters	CA-AKI	HA-AKI	T value	P value
Hemoglobin	9.93 ± 1.58	9.56 ± 2.04	0.88	0.38
TLC (mm3)	7029.37 ± 2102.32	7264.28 ± 4160.39	0.37	0.71
APC (lakhs)	3.03 ± 0.74	2.71 ± 0.95	1.62	0.11
RBS (mg/dl)	105.9 ± 5.85	105.72 ± 4.35	0.12	0.90
Serum Creatinine (mg/dl)	2.94 ± 1.21	1.13 ± 0.14	6.32	<0.001
Blood Urea (mg/dl)	96.05 ± 44.71	107.17 ± 64.1	0.90	0.37
Serum Sodium (meq/l)	135.67 ± 4.99	135.94 ± 4.88	0.21	0.83
Serum Potassium (meq/l)	4.16 ± 0.86	3.88 ± 0.65	1.32	0.19
Total Protein (g/dl)	6.23 ± 0.7	6.45 ± 0.75	1.22	0.23
Serum Albumin(g/dl)	2.95 ± 0.51	3.1 ± 0.68	1.09	0.28

In the present study, the most significantly affected biochemical parameter in CA-AKI as well as HA-AKI was serum creatinine (2.94 ± 1.21 mg/dL vs 1.13 ± 0.14 mg/dL; p<0.001) as compared to the other parameters.

TABLE 10: Creatinine and AKI Distribution

	CA-AKI N = 102	HA-AKI N = 18	T value	P value
S. Creatinine (At admission)	2.94 ± 1.21	1.13 ± 0.14	6.32	<0.001

S. Creatinine (After 48 hrs)	2.95 ± 1.34	4.11 ± 2.44	2.93	0.004
S. Creatinine (At 7th day from the day of admission)	1.02 ± 0.28	0.69 ± 0.63	3.66	<0.001

In the present study, the serum creatinine values of HA-AKI and CA-AKI patients at admission was 1.13 ± 0.14 and 2.94 ± 1.21 respectively, in which the difference was found to be statistically significant; p<0.001. After 48 hours of admission, serum creatinine of CA-AKI was 2.95 ± 1.34 and HA-AKI was 4.11 ± 2.44, which was also found to be statistically significant; p=0.004. Even, the difference in serum creatinine values of patients with HA-AKI and CA-AKI on 7th day from the day of admission was statistically significant (CA-AKI = 1.02 ± 0.28 and HA-AKI = 0.69 ± 0.63; p<0.001).

Therefore, the difference in serum creatinine values at admission, after 48 hrs and on 7th day from admission, in both, CA-AKI as well as HA-AKI patients was found to be statistically significant (p<0.001, p=0.004, p<0.001 respectively).

TABLE 11: KDIGO and AKI Distribution

	CA-AKI	HA-AKI	x ² value	P value
KDIGO 1	32 (31.4%)	3 (16.6%)	1.61	0.45
KDIGO 2	18 (17.6%)	4 (22.2%)		
KDIGO 3	52(50.9%)	11 (61.1%)		
Total	102 (85%)	18 (15%)		

In the present study, out of the 102 patients with CA-AKI, 52 (50.9%) were found to be in KDIGO stage 3; 32 (31.4%) in KDIGO stage 1 and 18 (17.6%) in KDIGO stage 2. Out of the 18 patients with HA-AKI, 11 (61.1%) were found to be in KDIGO stage 3; 4 (22.2%) in KDIGO stage 2 and 3 (16.6%) in KDIGO stage 1. Thus, the highest percentage of patients were in KDIGO stage 3, in both the groups of AKI.

It has been observed that there was insignificant association between stages of KDIGO and Type of AKI (p = 0.45)

TABLE 12: KDIGO STAGE AND ITS ETIOLOGICAL DISTRIBUTION

Etiological	KDIGO-1	KDIGO-2	KDIGO-3	Total
Acute Diarrheal Disease	18 (30.5%)	13 (22%)	28 (47.4%)	59 (46.6%)
Snake Bite	9 (36%)	2 (8%)	14 (56%)	25 (20%)
Sepsis	2 (16.7%)	3 (25%)	7 (58.3%)	12 (10%)
Tropical Acute Febrile Illness	2 (16.7%)	2 (16.7%)	8 (66.6%)	12 (6.6%)
Acute Glomerulonephritis	2 (50%)	1 (25%)	1 (25%)	4 (3.3%)
Ureteric calculus	2 (66.7%)	0	1 (33.3%)	3 (2.5%)
Super vasmol Poisoning	0	1 (50%)	1 (50%)	2 (1.6%)
Pigment Nephropathy	0	0	2 (100%)	2 (1.6%)
NSAID Induced	0	0	1 (100%)	1 (0.8%)
Total	35 (29.1%)	22 (18.3%)	63 (52.5%)	120 (100%)
x² value	12.68			
P value	0.696			

In the present study of 120 patients of AKI with the above etiologies, 35 (29.1%), 22 (18.3%) and 63 (52.5%) patients respectively were found in the KDIGO 1, KDIGO 2 and KDIGO 3 stages respectively. Thus, among the 3 stages of AKI by KDIGO criteria, maximum percentage of patients was in stage 3. It has been observed that there was insignificant association between stages of KDIGO and etiological profile (p = 0.696).

TABLE 13: MANAGEMENT OF AKI

Renal Replacement Therapy	CA- AKI	HA-AKI	Total
Conservative	75 (69.6%)	10 (55.5%)	85 (70.8%)
Hemodialysis	21 (20.5%)	6 (33.3%)	27 (22.5%)

Peritoneal Dialysis	6 (5.8%)	2 (11.1%)	8 (6.6%)
Total	102 (85%)	18 (15%)	120 (100%)
x² value	2.430		
P value	0.297		

In the present study, out of the 85 patients (70.8%) who were managed conservatively, 75 (69.6%) had CA-AKI and 10 (55.5%) had HA-AKI. From the 27 patients (22.5%) who required hemodialysis, 21 patients (20.5%) had CA-AKI and 6 patients (33.3%) had HA-AKI. Whereas, from the 8 patients (6.6%) in which peritoneal dialysis was done, 6 patients (5.8%) had CA-AKI and 2 patients (11.1%) had HA-AKI. Thus, it was found that compared to CA-AKI (26.3%), the need for dialysis was higher in patients with HA-AKI (44.4%). It has been observed that there was insignificant association between type of renal replacement therapy and type of AKI (p = 0.297).

TABLE 14: ETIOLOGY WISE MANAGEMENT DISTRIBUTION

Etiological	Renal Replacement Therapy		
	Conservative	Hemodialysis	Peritoneal Dialysis
Acute Diarrheal Disease	46 (38.3%)	9 (7.5%)	4 (3.3%)
Snake Bite	14 (11.6%)	9 (7.5%)	2 (1.6%)
Sepsis	7 (5.8%)	3 (2.7%)	2 (1.6%)
Tropical Acute Febrile Illness	10 (11.7%)	2 (1.6%)	0
Acute Glomerulonephritis	3 (2.5%)	1 (0.8%)	0
Ureteric calculus	2 (1.6%)	1 (0.8%)	0
Super vasmol Poisoning	2 (1.6%)	0	0
Pigment Nephropathy	0	2 (1.6%)	0
NSAID Induced	1 (0.8%)	0	0
Total	85 (70.9%)	27 (22.5%)	8 (6.6%)
2 value	16.79		
P value	0.399		

In all, 35 (29.1%) patients required dialytic support, of which 27 (22.5%) were treated by hemodialysis and 8 (6.6%) by peritoneal dialysis. The remaining 85 patients (70.8%) were treated conservatively. It has been observed that there was insignificant association between type of renal replacement therapy and etiological profile (p = 0.399).

TABLE 15: OUTCOME WISE DISTRIBUTION

Outcome	CA- AKI	HA-AKI	No of Patients
Complete Recovery	94 (92.1%)	9 (50%)	103 (85.8%)
Partial Recovery	3 (2.9%)	2 (11.1%)	5 (4.1%)
Mortality	5 (4.9%)	7 (38.8%)	12 (10%)
Total	102 (85%)	18 (15%)	120
x² value	23.292		
P value	<0.001		

Regarding the outcome of AKI, 103 patients (85.8%) had complete recovery, of which, 94 (92.1%) had CA-AKI and 9 (50%) had HA-AKI. 5 patients (4.1%) had partial recovery. The overall in hospital mortality rate was 10%. Moreover, hospital acquired AKI has found significantly higher mortality (38.8%) than community acquired AKI (4.9%). It has been observed that there was significant association between outcome of patients and type of AKI (p<0.001).

SUMMARY AND CONCLUSION

120 cases of acute kidney injury (classified by KDIGO criteria), who presented to Geetanjali Medical College and Hospital, Udaipur, from January 2017 to October 2018, were studied. These cases were further divided into CA-AKI and HA-AKI and studied regarding the demographic characteristics, clinical presentation, etiology and outcome.

- Out of the 120 patients of AKI, 102 (85%) patients were

classified as having CA-AKI and 18 (15%) patients as having HA-AKI. Thus, the frequency of CA-AKI was significantly higher as compared to HA-AKI. (p<0.001)

- The mean age of patients with CA-AKI was 51.54 ± 14.93 and HA-AKI was 53.22 ± 7.22, which was statistically not significant. The maximum number of patients with CA-AKI were in the 6th and 7th decades of life whereas maximum patients with HA-AKI were in the 5th and 6th decades of life.
- Out of 120 patients of AKI, 70 patients (58.3%) were males, while 50 (41.6%) were females. The sex ratio was 1.4:1. Both, CA-AKI and HA-AKI had male predominance.
- The most common clinical feature was oliguria (83.3%) in HA-AKI and vomiting (59.8%) in patients with CA-AKI. Thus, we observed that there is significant association between clinical features and type of AKI i.e. there was change in the clinical feature with the type of AKI (p<0.001).
- Co-morbidities were present in 17.5% patients. We found that the commonest co-morbidity in patients with CA-AKI was HTN (5.8%) and in HA-AKI was DM (27.7%).
- We found that the commonest etiology in patients with HA-AKI was sepsis (66.6%) followed by acute glomerulonephritis (16.6%). In CA-AKI patients, the most common etiology was acute diarrheal disease (57.8%) followed by snake bite (24.5%). Thus, we observed that there was significant difference in etiological profile with type of AKI (p<0.001).
- We observed that the difference in serum creatinine values at admission, after 48 hrs and at 7th day from admission in both, CA-AKI as well as HA-AKI patients was found to be statistically significant (p < 0.001).
- The highest percentage of patients were in KDIGO stage 3, in both the groups of AKI (50.9% and 61.1% in CA-AKI and HA-AKI respectively).
- Maximum patients (70.8%) were managed conservatively while, 29.1% patients required dialytic support.
- We observed that the need for dialysis was higher in patients with HA-AKI (44.4%) as compared to CA-AKI (26.3%).
- We found that patients with CA-AKI had significantly higher rate of complete recovery than HA-AKI patients.
- We observed significantly higher mortality rates in patients with HA-AKI (38.8%) as compared to CA-AKI (4.9%). Thus, there was significant association between outcome of patients and type of AKI (p<0.001).

CONCLUSION

From the above study we concluded that the frequency of community acquired AKI was much higher as compared to hospital acquired AKI. Both community and hospital acquired AKI had male predominance. The clinical and epidemiological characteristics of community and hospital acquired AKI vary considerably. HA-AKI is common in ICUs, whereas CA-AKI is common in medical wards. Sepsis was the most common cause of HA-AKI, whereas, acute diarrheal disease and snake bite were frequent causes of CA-AKI. A major proportion of CA-AKI in the current study had preventable etiologies. Higher mortality was found in HA-AKI than CA-AKI. The underlying co-morbidities and vital organ dysfunction appears to be a major predictor of death.

Patients with CA-AKI have better short and long-term outcomes as compared to HA-AKI. The reason may be the difference in aetiology as most patients of CA-AKI had volume depletion which could be corrected easily.

AKI is a catastrophic disease and to deal with such a cataclysmic disease leading to high mortality and morbidity, frequent epidemiological studies from all parts of country are needed to devise the preventive and therapeutic strategies for this condition. Early recognition, early fluid resuscitation, effective anti-infective treatment, appropriate antidotes and timely referral of established AKI patients to centers with dialysis facilities can improve AKI outcome.

REFERENCES

1. Alan F Almeida, Jatin P Kothari , Acute kidney injury, API Text book of medicine; Y P Munjal: 9th edition; 2012:Jaypee; p. 1291.
2. SushrutS.Waikar, Joseph V. Bonventre-Acute Kidney Injury In Dan L.Lango, Dennis L Kasper., Joseph Loscalzo, J.Larry Jameson et.al eds. Harrison's principles of internal medicine, 18th ed. New york, Mcgrawhill, 2012 .p. 2294.

3. Utas C, Yalcindag C, Taskapan H, Guven M, Oymak O, Yucesoy M. Acute renal failure in central Anatolia. *Nephrol Dial Transplant*. 2000; 15: p. 152–5.
4. Muthuseethupathi MA, Shivakumar SJ. Acute renal failure in South India. *J Assoc of Physicians India*. 1987; 36(7): p. 504–7.
5. Prakash J, Tripathi K, Malhotra V, Kumar O, Srivatsava PK. Acute renal failure in Eastern India. *Nephrol Dial Transplant*. 1995; 10: p. 2009–12.
6. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, and the Acute Dialysis Quality Initiative workgroup. Acute renal failure— definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative Group. *Crit Care* 2004; 8: p. 204–12.
7. Kellum JA, Ronco C, Mehta R, Bellomo R: Consensus development in acute renal failure: The Acute Dialysis Quality Initiative. *Curr Opin Crit Care* 2005, 11: p. 527-32.
8. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R: Risk factors for acute renal failure: inherent and modifiable risks. *Curr Opin Crit Care* 2005, 11: p. 533-6.
9. Mehta RL, Kellum JA, Shah SV et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11: p. R31